Wassel Al Fakhoury

President, Acme Clinical Trials Inc.

Wassel is a consultant and non-executive director advising companies, businesses and high net worth individuals globally on M&A transactions, strategy and corporate governance.

Wassel is a corporate and M&A counsel with experiences covering complex and sensitive corporate and M&A transactions in addition to having been a board member for some of the largest publicly traded companies and sovereign funds in the Middle East and North Africa (MENA) region.

Wassel’s skill set not only includes more than 19 years of corporate counsel experience leading and managing M&A and privatization deals (including corporate structuring and restructuring of complex projects and businesses in different jurisdictions) exceeding USD100 billion in total value but also 3 years of board membership for conglomerate companies and sovereign funds in the GCC with a work force exceeding 50,000 where he was in charge of overall strategy, management, organizational governance, board governance and assurance of executive performance.

Wassel sat on the boards of:

• Arabtec Holding PJSC, a public company listed on the DFM and one of the leading engineering and construction group of companies specializing in complex projects in the MENA region.
• Depa Limited, a public company listed on the Nasdaq Dubai in the DIFC and one of the world’s largest interior contractors.
• Jordan Wood Industries Company as Chairman, a public shareholding company listed on the Amman Stock Exchange in Jordan.
• Private companies in the U.S and Europe.

Wassel served as the General Counsel for Aabar Investments PJS, the Abu Dhabi-based sovereign fund and diversified investment conglomerate. Wassel has also held a number of other senior roles.

Wassel has successfully structured, managed and led unprecedented transactions and is invited regularly as a speaker at conferences on M&A transactions and corporate governance in MENA.

Wassel graduated from the University of Cambridge/Judge Business School, obtaining Executive MBA and is also a graduate of the University of Pennsylvania and Wharton Business School, obtaining and LL.M. and Wharton Business & Law Certificate.

Xu.H Ji

Director, Acme Clinical Trials Inc.

Xu.H Ji is a highly rated and respected consultant with years of experience handling high value and complex commercial M&A, cross-border investment, and financial services.

He advises extensive range of clients, including large-scale state-owned enterprises, listed companies, multinational companies, financial institutions, private equity and VCs. The advisory offered to his clients covers structural design of cross-border investment, outbound investment strategy and implementation, regulatory compliance for the transactions with complicated cross-border structures. The total investment profile of his clients exceeds $120 billion per annual.

He has in-depth knowledge on the free trade zone in China. He coordinates local authorities with national and international organizations, including United Nations Industrial Development Organization, for major capital inbound and outbound funding.

He is a successful entrepreneur and founding director of few businesses with rapid growth and acquisitions by large enterprises.

Xu.H Ji graduated from the University of Cambridge. He holds MBA degree and LL.M degree.

Nofel Izz

C.E.O, Acme Clinical Trials Inc.

Nofel Izz an inventor and entrepreneur who is focused on developing solutions for global public health issues. His past experiences creating recognition programs, working with branding and founding an employment company have led him to a new career as an inventor. Nofel started out by developing a successful employee recognition program for Canadian banks that are still in use and founded a company which became the largest jobs portal in the Middle East, with 8.5 million users with over 10,000 employers. Now he works at creating solutions to address deficits in various aspects of life.

Nofel is currently heading 19 startup and inventions at various levels worth $230M that includes Artificial Intelligent application developments in clinical trials software using analytics for Pharmaceuticals.

Nofel Izz, Computer Science / MBA, University of Cambridge, MPH, Yale School of Public Health.